... with Theravance -- Anoro -- that could be an even bigger winner. Glaxo also hopes to gain market share in the HIV/AIDS arena through its ViiV Healthcare joint venture with Pfizer ( ) and Japanese drugmaker Shionogi . ViiV counts 11 drugs in its ...
http://www.fool.com/investing/general/2013/11/19/is-warren-buffett-wrong-about-this-health-care-gia.aspx
http://www.fool.com/investing/general/2013/11/19/is-warren-buffett-wrong-about-this-health-care-gia.aspx
No comments:
Post a Comment